Clinical Outcomes & Success Metrics at EPIA
High-Performance Fertility, Backed by Rigorous Data
At the Egg Preservation Institute of Asia (EPIA), we combine clinical expertise, advanced embryology, and individualized care protocols to deliver above-average success rates in fertility preservation and assisted reproduction.
We benchmark our performance against global standards (SART, ESHRE) and maintain a continuous internal audit of all treatment cycles, stratified by age, indication, and protocol type.
Vitrification Outcomes (2024 Cohort Data)
I. Egg Freezing (Oocyte Cryopreservation)
- Average MII Oocytes per Cycle (Age <35): 14.7
- Post-Thaw Survival Rate (MII Oocytes): 99.3%
- ICSI Fertilization Rate (Post-Thaw): 78.6%
- Blastocyst Conversion Rate: 56.4%
- Implantation Rate per Frozen Embryo Transfer:
- Age <35: 61.2%
- Age 35–37: 52.8%
- Age 38–40: 44.9%
- Age >40: 31.6%
- Age <35: 61.2%
Fresh and Frozen Embryo Transfers (All Cycles, 2024)
II. In Vitro Fertilization (IVF)
- Clinical Pregnancy Rate per Embryo Transfer (ET):
- <35: 68.5%
- 35-37: 59.7%
- 38-40: 48.3%
- 40: 34.1%
- <35: 68.5%
- Live Birth Rate per ET (all ages): 48.2%
- Average # of Embryos Transferred: 2.1 (Two embryo transfer preferred)
- Preimplantation Genetic Testing for Aneuploidy (PGT-A) Usage Rate: 62%
- Euploid Embryo Rate (by Age Group):
- <35: 62%
- 35-37: 52%
- 38-40: 38%
- 40: 21%
- <35: 62%
Observed Impact (Subset Analysis, N=112, 2024)
III. “Conceive Plus” Fertility Optimization Protocol
Protocol Includes: IV micronutrient therapy, acupuncture (TCM-aligned), and oral antioxidant supplementation (CoQ10, DHEA, Myo-inositol).
- Improvement in AMH after 90 days: +18.4% (statistically significant)
- Increased AFC (antral follicle count): +2.1 follicles avg
- Enhanced Oocyte Maturity Rate: 91.7% vs. 75.4% (non-prep cohort)
- Improved Endometrial Thickness (on transfer day): 8.6 mm avg vs. 6.9 mm
IV. Supporting Infrastructure & Quality Control
- Lab Protocols:
- EmbryoScope time-lapse imaging
- Vitrification using Kitazato protocol
- ICSI for all frozen-thawed oocytes
- Laser-assisted hatching on Day 5 if required
- EmbryoScope time-lapse imaging
- Clinical Protocols:
- Individualized stimulation with GnRH-antagonist or mild stim
- Pre-cycle hormone mapping (AMH, FSH, LH, E2, TSH, PRL, DHEA-S)
- Luteal support optimization based on serum progesterone levels
- Individualized stimulation with GnRH-antagonist or mild stim
- Data Systems:
- REDCap-based tracking system
- Monthly performance audits & annual data release
- External validation in progress with partner academic institution (Q3 2025)
- REDCap-based tracking system
V. Success Benchmarks Compared to Regional & Global Averages
| Metric | EPIA | Asia Regional Avg | Global Avg (SART/ESHRE) |
|---|---|---|---|
| Egg Thaw Survival | 92.3% | ~85% | 90% |
| IVF Pregnancy (Age <35) | 68.5% | ~52% | 56–60% |
| Live Birth per ET | 48.2% | ~38% | 40–45% |
| Euploid Embryo Rate (35–37) | 52% | ~42% | 45–50% |
VI. Summary of Strengths
- Consistently higher-than-average success rates in IVF, egg freezing, and embryo transfer
- Evidence-based adjunct treatments (e.g., Conceive Plus) show measurable biomarker improvements
- State-of-the-art lab technology and strict clinical governance
- Transparent reporting and outcomes-based care pathways